FGF23 and chronic kidney disease: Because TIO-analog phenotypes are uncommon, a multicenter prospective registry of CKD patients with confirmed FGF-23-mediated phosphate wasting treated with burosumab could be a feasible next step to clarify safety signals, patient response, and real-world treatment patterns.